Rockland Immunochemicals, Inc. Awarded SBIR Funding to Develop Antibody-Based Point of Care Device for the Diagnosis of Sickle Cell Disease

7 Sept 2014
Charlotte Moore
Administrator / Office Personnel

Industry news

Rockland Immunochemicals, Inc. (Rockland) announced the award of a $224,473 Small Business Innovation Research (SBIR) grant from the NIH National Heart Lung and Blood Institute (NHLBI) to develop an antibody-based point of care device for the diagnosis of Sickle Cell Disease (SCD), a mutation that is carried in approximately 7% of the world’s population. Rockland secured the award by demonstrating the technology and processes it deploys to develop and to produce leading edge life science tools for basic and clinical research focused on functional genomics and drug discovery markets.

Sickle cell anemia (SCA) is the most common form of SCD which is the fifth most common genetic disorder in the world. SCD occurs when red blood cells are unable to carry adequate oxygen throughout the body due to their deformation. SCD is extremely painful in those affected. Early detection of SCD can help reduce the risk of life-threatening infections and increase the odds for survival. Also, diagnosis enables treatment with pain medication that can ease most symptoms, including abdominal, chest and bone pain, fatigue, shortness of breath, accelerated heart rate, delayed puberty, stunted growth, fever, and leg ulcers.

Currently, there are no simple and cost effective screening tests that can differentiate patients with the sickle cell trait (HbAS) from sickle cell disease conditions (HbSS, HbSC and HbS β-thalassemias). “Rockland’s antibody technology platform will help to overcome these barriers tremendously. We will create novel hemoglobin isoform-specific antibodies and configure a lateral flow point-of-care assay.” said Dr. Carl Ascoli, Rockland’s Chief Science Officer. “As a result of this project, the antibody-based lateral flow point-of-care device will allow rapid and inexpensive diagnosis of Sickle Cell Disease in infants and young children in industrialized and low-income and low-resource settings.”

Links

Tags

AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Point of Care SolutionsPoint of care solutions provide medical diagnostics and treatments at or near the site of patient care. These technologies offer rapid results, helping healthcare providers make quick decisions. From glucose monitors to molecular diagnostics, point of care solutions are transforming healthcare delivery by reducing wait times and improving patient outcomes. Explore the best point of care products in our peer-reviewed product directory, compare options, check reviews, and get pricing directly from manufacturers.Therapeutic AntibodiesTherapeutic antibodies are antibodies engineered for use in treating diseases. They can be designed to target specific antigens, blocking harmful interactions or modulating immune responses. Therapeutic antibodies are critical in treating conditions like cancer, autoimmune disorders, and infectious diseases. Explore the best therapeutic antibody products in our peer-reviewed product directory; compare options, check reviews, and get pricing directly from manufacturers.